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While a postdoc in Philippe Sansonetti’s 
laboratory at the Pasteur Institute in 
Paris, Philpott and her colleagues 
made the surprising discovery that the 
toll-like receptors, which initiate inflam-
mation in response to bacterial lipopoly-
saccharides and other pathogen-derived 
molecules, were not the only pathogen-
sensing receptors in town. Along with 
Gabriel Nuñez at the University of 
Michigan, they had found a second set 
of bacterial detectors in the cytosol, 
which they dubbed nucleotide-binding 
oligomerization domain (NOD)-like 
receptors. NOD1 and 2 respond to 
specific bacterial peptidoglycan motifs 
by activating the JNK and NF-B sig-
naling  pathways (1). NOD2 turned 
out to be a sensor of muramyl dipep-
tide (MDP), a cell wall component of 
gram-positive and -negative bacteria 
that is found in many 
adjuvant preparations. 
The group later found 
that a mutation in 
NOD2, commonly 
found in Crohn’s dis-
ease patients, abrogates 
the immune response 
to MDP, suggesting 
that NOD2’s ability to 
detect this ligand helps 
prevent the develop-
ment of this autoim-
mune disease (2).
After becoming a 
group leader at the Pas-
teur Institute in 2002, 
Philpott continued to 
explore the role of 
NOD-like receptors in initiating innate 
and adaptive immune responses to a 
variety of bacterial pathogens, such as 
Helicobacter pylori and Listeria monocytogenes 
(3, 4). In 2006, she and her partner—and 
frequent collaborator—Stephen Girardin 
moved to the University of Toronto, 
where they continue to investigate the 
role of NOD-like receptors in disease. 
Philpott is also studying the role of 
NOD1 and NOD2 in maintaining 
homeostasis in the gut, where immune 
cells must tolerate millions of commensal 
bacteria to avoid provoking autoimmune 
disease (5).
PATHOGENS IN PARIS
You spent nine years in Paris, fi  rst as a 
postdoc and then as a group leader. What 
brought you there, and what made you 
decide to stay?
I did my PhD in Toronto on host–
pathogen interactions. So, when I decided 
to do a postdoc, I was looking for a 
laboratory where I could continue 
that work, and I really wanted to go to 
Europe. If you ask anybody in the world 
who are the top people working in 
host–pathogen interactions, they would 
say Philippe Sansonetti and Pascale 
Cossart, who are both at the Pasteur 
Institute. So I asked Philippe Sansonetti 
if it would be possible to do a postdoc 
in his laboratory.
He said, “Yes, but I have a two-year 
waiting list.” So I waited for two years. 
I finished my PhD and worked as a 
postdoc at McMaster University [in 
Ontario] with Dr. Mary Perdue. Then I 
got some funding and went to Philippe’s 
laboratory, and it was great. I loved it.
Once we made the initial discovery 
about NOD proteins and had a paper, 
I was lucky enough to be chosen by 
the Pasteur Institute for one of their 
first independent group leader posi-
tions. It was actually the first time 
they had done this in France. Usually 
as a young scientist you join a senior 
scientist’s laboratory, develop your 
group within the bigger laboratory, 
and then someday you can break 
away. But this was the first time they 
actually offered young group leader 
positions—it offered complete inde-
pendence to the young scientist.
What were you looking for when you 
discovered the NOD proteins?
We were looking for a receptor that 
would respond to bacterial infection. 
We got interested in NOD because 
there’s a family of these proteins in 
plants that do very similar things. When 
a plant cell gets infected, it can detect 
pathogens that come into the cytosol—
what’s called the hypersensitivity re-
sponse. We thought there might be 
something similar going on in mam-
malian cells because we could see that 
these proteins could be activated after 
an intracellular bacterial infection. So 
now we know that NODs are ex-
pressed by a number of diff  erent or-
ganisms; even sea urchins have similar 
proteins. It’s a huge evolutionarily con-
served family.
Going back a little further, I see that you 
took three years off   between getting your 
bachelor’s degree and starting your PhD. 
What did you do?
I worked as a technician in Calgary for 
a lovely man named Decker Butzner, 
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“We think 
NOD2, in 
particular, 
may play a 
role in making 
immune cells 
in the mucosa 
of the 
intestine more 
tolerant to 
the bacterial 
flora.”
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who is a pediatric gastroenterologist. 
He showed me what research could be 
like. We did intestinal physiology, so I 
have a good basis in the intestine, 
which really makes an impact on my 
work now.
Is that where you became interested in 
host–pathogen interactions?
Exactly. From the basic studies we were 
doing on physiology, I wanted to look at 
how bacteria interacted 
with the intestine, and I 
did my PhD with another 
pediatric gastroenterolo-
gist, Phil Sherman, who 
was working on entero-
pathogenic E. coli, which 
causes diarrhea.
What is it with you 
and the pediatric 
gastroenterologists?
I know! My fi  rst student 
was a pediatric gastroen-
terologist, and now I 
have a pediatric gastroenterologist fel-
low in my laboratory. It’s a funny con-
nection, but it’s great. It’s nice to have 
the medical people around. They have a 
way of looking at questions diff  erently.
NOD AND AUTOIMMUNITY
How do NOD2 mutations contribute to 
Crohn’s disease?
About 30% of Crohn’s disease patients 
have a mutation in NOD2. The muta-
tion was discovered in 2001, and it was 
the fi   rst susceptibility gene that was 
linked to Crohn’s. It caused a huge uproar 
in the community. Everybody and their 
dog wanted to work on it, but we had a 
head start because we’d already been 
working on the pathway a little bit. We 
discovered the ligand for NOD2 in 
2003, along with Gabriel Nuñez. But its 
role in the pathogenesis of the disease is 
still unclear.
What is your hypothesis?
Since NOD-like receptors were fi  rst 
discovered as innate immune detectors 
of microbes, the fi  rst idea that everyone 
had was that they play a role in host 
defense, which I think makes sense. 
They’re there to detect any bacteria 
that might come into the host and they 
initiate an infl   ammatory response to 
get rid of that pathogen. But people are 
now coming around to the idea that in-
stead of their major role being in host 
defense, they probably play more of a 
role in homeostasis—especially in the 
context of the intestine, where gut 
epithelial cells are in constant contact 
with huge masses of bacteria and diff  erent 
microbes. We think NOD2, in particular, 
may play a role in making immune cells 
in the mucosa of the intestine more 
tolerant to the bacterial fl  ora.
Rather than being a true defense 
molecule (although it might play that 
role as well), under normal conditions 
NOD2 is probably providing homeo-
static signals to maintain the gut environ-
ment in a state that’s tolerant of its flora.
So immune cells in the intestines of 
Crohn’s patients are overreacting to bacterial 
exposure, and that causes infl  ammation?
Yes. It’s clear that bacterial fl  ora play a 
key role in the disease. A number of 
studies in animal models and in humans 
have found that [Crohn’s] is absolutely 
fl   ora driven. We don’t know if it’s a 
specifi  c bacteria, but if you house mice 
that have the tendency to develop colitis 
in germ-free conditions, they don’t 
develop the disease. And if you put 
them back in conventional facilities 
where there are bacteria and microbes, 
then they immediately get the disease.
If we could somehow give Crohn's 
disease patients with a mutation in 
NOD2 a signal that is normally driven 
by the protein, then we could go around 
the NOD2 block. So what we’re work-
ing on at the moment is to define the 
factors that are produced after NOD2 
is triggered. And if we could give those 
factors to Crohn’s patients exogenously, 
it could help to tolerize their immune 
cells. It’s kind of pie in the sky stuff, 
but it keeps me coming to work.
And when you’re not at work, what are 
you doing?
Running after the kids on a daily basis. 
Stephen and I have a fi  ve-year-old 
daughter and a two-and-a-half-year-
old son. I think we’re pretty good role 
models for other scientists who want to 
have kids. They see us working nine to 
fi  ve, and never working on weekends. 
They don’t notice that from eight to 
midnight, Stephen and I are often 
working away, but I wouldn’t trade it 
for anything. I’m happy to work those 
kinds of hours; at least we can spend the 
time as a family.
Do you have any advice for young female 
scientists who are concerned about having 
time for a family one day?
We recently had a lunch with our col-
leagues in the immunology depart-
ment, and we were talking about 
women and science. And I asked the 
men, “Has anyone ever asked you how 
you balance your family life and your 
work life?” They said, “No, never had 
that question.” But I have women stu-
dents coming in and 
asking me, “Can I do this 
academic life? Can I han-
dle both kids and work?” 
You have to be lucky and 
you have to have a very 
supportive partner, but 
you can do it. And you 
don’t have to work 18 
hours a day. You just have 
to be very effi   cient when you’re at work. 
That’s my advice to women students. 
Do it!
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“About 30% 
of Crohn’s 
disease 
patients have 
a mutation 
in NOD2.”
“NODs are 
expressed by 
a number of 
different 
organisms; 
even sea 
urchins have 
similar 
proteins.”